Sugi Predict

Sugi Predict / Compounds / SCHEMBL2594483

SCHEMBL2594483

SCHEMBL2594483

CCOC(=O)c1cn(Cc2c(F)cccc2F)nn1

nearest known ligand 0.67

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 4/20 0.67
▸ LMNA P02545 2/20 0.67
▸ CA5A P35218 1/20 0.66
▸ SMN1; SMN2 Q16637 2/20 0.65
▸ HPGD P15428 1/20 0.65
▸ CYP2C19 P33261 1/20 0.53
▸ KLKB1 P03952 1/20 0.52
▸ GLA P06280 1/20 0.51
▸ TP53 P04637 1/20 0.51
▸ POLB P06746 1/20 0.51
▸ MAPK1 P28482 2/20 0.50
▸ KDM4E B2RXH2 1/20 0.48
▸ MEN1 O00255 1/20 0.47
▸ TSHR P16473 1/20 0.47
▸ KMT2A Q03164 1/20 0.47
▸ CYP1A2 P05177 1/20 0.47
▸ GAA P10253 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL461526 0.87 CA5A (0.69) ALDH1A1LMNACA5ASMN1; SMN2HPGD
SCHEMBL8151152 0.84 CA5A (0.73) ALDH1A1LMNACA5ASMN1; SMN2HPGD
SCHEMBL8164538 0.84 CA5A (0.64) ALDH1A1LMNACA5ASMN1; SMN2HPGD
SCHEMBL6738882 0.82 CA5A (0.74) ALDH1A1LMNACA5ASMN1; SMN2HPGD
SCHEMBL15827895 0.81 CA5A (0.62) ALDH1A1LMNACA5ASMN1; SMN2HPGD
SCHEMBL460913 0.81 CA5A (0.76) ALDH1A1LMNACA5ASMN1; SMN2HPGD
SCHEMBL10668049 0.81 ALDH1A1 (0.55) ALDH1A1LMNACA5ASMN1; SMN2HPGD
SCHEMBL893141 0.80 ALDH1A1 (1.00) ALDH1A1LMNASMN1; SMN2HPGDKLKB1
Rufinamide SCHEMBL230448 0.80 CA5A (1.00) ALDH1A1LMNACA5ASMN1; SMN2HPGD
Rufinamide SCHEMBL20769779 0.80 CA5A (1.00) ALDH1A1LMNACA5ASMN1; SMN2HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117105873-A Preparation method of rufeamide intermediate 宿州亿帆药业有限公司 2023-11-24 — — CN disclosed
CN-114369070-B Preparation process of rufinamide 海南医学院 2023-04-14 — — CN disclosed
CN-114369070-A Preparation process of rufinamide 海南医学院 2022-04-19 — — CN disclosed
EP-3250563-B1 SUBSTITUTED TRIAZOLES AND METHODS RELATING THERETO NEUROCRINE BIOSCIENCES INC (US) 2022-01-12 — — EP disclosed
US-11021449-B2 Substituted triazoles and methods relating thereto NEUROCRINE BIOSCIENCES, INC. (US) 2021-06-01 — — US disclosed
US-20200399229-A1 SUBSTITUTED TRIAZOLES AND METHODS RELATING THERETO NEUROCRINE BIOSCIENCES, INC. 2020-12-24 — — US disclosed
CN-107406420-B Substituted triazoles and methods related thereto 纽罗克里生物科学有限公司 2020-11-06 — — CN disclosed
US-10738017-B2 Substituted triazoles and methods relating thereto NEUROCRINE BIOSCIENCES, INC. (US) 2020-08-11 — — US disclosed
US-20190169137-A1 SUBSTITUTED TRIAZOLES AND METHODS RELATING THERETO NEUROCRINE BIOSCIENCES, INC. 2019-06-06 — — US disclosed
US-10206874-B2 Rufinamide solid dispersion HETERO RESEARCH FOUNDATION (IN) 2019-02-19 — — US disclosed
US-8884026-B2 Process for preparing rufinamide intermediate LABORATORIOS LESVI, S.L. (ES) 2014-11-11 — — US disclosed
US-8884026-B2 Process for preparing rufinamide intermediate LABORATORIOS LESVI, S.L. (ES) 2014-11-11 — — US disclosed
US-8884026-B2 Process for preparing rufinamide intermediate LABORATORIOS LESVI, S.L. (ES) 2014-11-11 — — US disclosed
EP-2563766-B1 IMPROVED PROCESS FOR PREPARING RUFINAMIDE INTERMEDIATE LESVI LABORATORIOS SL (ES) 2014-06-25 — — EP disclosed
WO-2014013511-A2 RUFINAMIDE SOLID DISPERSION HETERO RESEARCH FOUNDATION (IN) 2014-01-23 — — WO disclosed
EP-2563766-A1 IMPROVED PROCESS FOR PREPARING RUFINAMIDE INTERMEDIATE Laboratorios Lesvi, S.L. (ES) 2013-03-06 — — EP disclosed
US-20130045998-A1 PROCESS FOR PREPARING RUFINAMIDE INTERMEDIATE LABORATORIOS LESVI, S.L. (ES) 2013-02-21 — — US disclosed
US-20130045998-A1 PROCESS FOR PREPARING RUFINAMIDE INTERMEDIATE LABORATORIOS LESVI, S.L. (ES) 2013-02-21 — — US disclosed
US-20130045998-A1 PROCESS FOR PREPARING RUFINAMIDE INTERMEDIATE LABORATORIOS LESVI, S.L. (ES) 2013-02-21 — — US disclosed
WO-2011135105-A1 IMPROVED PROCESS FOR PREPARING RUFINAMIDE INTERMEDIATE LABORATORIOS LESVI, S.L. (ES) 2011-11-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130045998-A1 PROCESS FOR PREPARING RUFINAMIDE INTERMEDIATE CYP3A5, CYP3A4, CYP4B1 ALDH1A1 392/4885LMNA 3096/4885CA5A 69/4885
US-11021449-B2 Substituted triazoles and methods relating thereto CYP3A43, OTC, GRIN3A ALDH1A1 259/4885LMNA 2322/4885CA5A 575/4885
US-10206874-B2 Rufinamide solid dispersion RUVBL2, RUVBL1, KIT ALDH1A1 1092/4885LMNA 3702/4885CA5A 3538/4885
US-20200399229-A1 SUBSTITUTED TRIAZOLES AND METHODS RELATING THERETO CYP3A43, OTC, GRIN3A ALDH1A1 259/4885LMNA 2322/4885CA5A 575/4885
US-10738017-B2 Substituted triazoles and methods relating thereto CYP3A43, OTC, GRIN3A ALDH1A1 259/4885LMNA 2322/4885CA5A 575/4885
US-20190169137-A1 SUBSTITUTED TRIAZOLES AND METHODS RELATING THERETO CYP3A43, OTC, GRIN3A ALDH1A1 259/4885LMNA 2322/4885CA5A 575/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.